Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)
NCT04581746 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1800
Last updated 2022-05-10
Summary
The non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients during COVID-19 epidemic. This change in care can have an impact on follow-up and access to treatment for PVVIH.
Conditions
- Virus-HIV
- Covid19
Interventions
- OTHER
-
questionnaire
bi-monthly questionnaire and then one visit with questionnaire and covid-19 test
Sponsors & Collaborators
-
Tourcoing Hospital
lead OTHER
Principal Investigators
-
Pauline THILL, MD · CH TOURCOING
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-25
- Primary Completion
- 2022-06-30
- Completion
- 2022-12-31
Countries
- France
Study Locations
More Related Trials
-
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01440569 ·Status: COMPLETED ·Phase: PHASE3
-
Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects
NCT00966329 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts
NCT01928407 ·Status: COMPLETED ·Phase: PHASE4
-
Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults
NCT00608569 ·Status: COMPLETED ·Phase: NA
-
Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy
NCT05303337 ·Status: RECRUITING
-
Antiretroviral Speed Access Program
NCT04897243 ·Status: RECRUITING
-
Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)
NCT00158457 ·Status: COMPLETED ·Phase: PHASE3
-
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST
NCT03858478 ·Status: UNKNOWN ·Phase: PHASE4
-
Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care
NCT01900080 ·Status: UNKNOWN ·Phase: NA
-
Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting
NCT01772940 ·Status: COMPLETED ·Phase: PHASE4
-
Optimisation of Care in Vulnerable HIV Infected Individuals
NCT03799276 ·Status: COMPLETED ·Phase: NA
-
Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults
NCT00196599 ·Status: COMPLETED ·Phase: PHASE2
-
Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors
NCT01458977 ·Status: COMPLETED ·Phase: PHASE4
-
Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)
NCT01048671 ·Status: COMPLETED
-
Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
NCT02269917 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Multicenter Study of the Relationship Between Virological Effectiveness and Compliance in HIV-1-infected Patients Treated With Bictegravir
NCT06902142 ·Status: RECRUITING
-
Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)
NCT00117494 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
NCT01967940 ·Status: COMPLETED ·Phase: PHASE3
-
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
NCT00532168 ·Status: COMPLETED ·Phase: PHASE4
-
Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.
NCT00386659 ·Status: TERMINATED ·Phase: PHASE4
-
HCV, HBV, HIV Testing During Consultation With Anesthesiologist
NCT04286347 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1
NCT04147325 ·Status: COMPLETED
-
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
NCT01029249 ·Status: COMPLETED
-
Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects
NCT00529243 ·Status: COMPLETED ·Phase: PHASE3
-
Cohort IMEA 070 -Lenacapavir Compassional
NCT06289361 ·Status: ACTIVE_NOT_RECRUITING